426 related articles for article (PubMed ID: 25692950)
1. Amyloidogenicity of p53: a hidden link between protein misfolding and cancer.
Gong H; Yang X; Zhao Y; Petersen RB; Liu X; Liu Y; Huang K
Curr Protein Pept Sci; 2015; 16(2):135-46. PubMed ID: 25692950
[TBL] [Abstract][Full Text] [Related]
2. Amyloidogenicity of p53: A Hidden Link Between Protein Misfolding and Cancer.
Gong H; Yang X; Zhao Y; Petersen RB; Liu X; Liu Y; Huang K
Curr Protein Pept Sci; 2014 Nov; ():. PubMed ID: 25440023
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.
Silva JL; Cino EA; Soares IN; Ferreira VF; A P de Oliveira G
Acc Chem Res; 2018 Jan; 51(1):181-190. PubMed ID: 29260852
[TBL] [Abstract][Full Text] [Related]
4. The Lys-Specific Molecular Tweezer, CLR01, Modulates Aggregation of the Mutant p53 DNA Binding Domain and Inhibits Its Toxicity.
Herzog G; Shmueli MD; Levy L; Engel L; Gazit E; Klärner FG; Schrader T; Bitan G; Segal D
Biochemistry; 2015 Jun; 54(24):3729-38. PubMed ID: 26030124
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases.
Cheng B; Gong H; Xiao H; Petersen RB; Zheng L; Huang K
Biochim Biophys Acta; 2013 Oct; 1830(10):4860-71. PubMed ID: 23820032
[TBL] [Abstract][Full Text] [Related]
6. Loss of the p53 transactivation domain results in high amyloid aggregation of the Δ40p53 isoform in endometrial carcinoma cells.
Melo Dos Santos N; de Oliveira GAP; Ramos Rocha M; Pedrote MM; Diniz da Silva Ferretti G; Pereira Rangel L; Morgado-Diaz JA; Silva JL; Rodrigues Pereira Gimba E
J Biol Chem; 2019 Jun; 294(24):9430-9439. PubMed ID: 31028175
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.
Ano Bom AP; Rangel LP; Costa DC; de Oliveira GA; Sanches D; Braga CA; Gava LM; Ramos CH; Cepeda AO; Stumbo AC; De Moura Gallo CV; Cordeiro Y; Silva JL
J Biol Chem; 2012 Aug; 287(33):28152-62. PubMed ID: 22715097
[TBL] [Abstract][Full Text] [Related]
8. Amyloidogenicity at a Distance: How Distal Protein Regions Modulate Aggregation in Disease.
Lucato CM; Lupton CJ; Halls ML; Ellisdon AM
J Mol Biol; 2017 May; 429(9):1289-1304. PubMed ID: 28342736
[TBL] [Abstract][Full Text] [Related]
9. Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation.
De Smet F; Saiz Rubio M; Hompes D; Naus E; De Baets G; Langenberg T; Hipp MS; Houben B; Claes F; Charbonneau S; Delgado Blanco J; Plaisance S; Ramkissoon S; Ramkissoon L; Simons C; van den Brandt P; Weijenberg M; Van England M; Lambrechts S; Amant F; D'Hoore A; Ligon KL; Sagaert X; Schymkowitz J; Rousseau F
J Pathol; 2017 May; 242(1):24-38. PubMed ID: 28035683
[TBL] [Abstract][Full Text] [Related]
10. The Gelsolin Pathogenic D187N Mutant Exhibits Altered Conformational Stability and Forms Amyloidogenic Oligomers.
Srivastava A; Singh J; Singh Yadav SP; Arya P; Kalim F; Rose P; Ashish ; Kundu B
Biochemistry; 2018 Apr; 57(16):2359-2372. PubMed ID: 29637772
[TBL] [Abstract][Full Text] [Related]
11. Effect of position-specific single-point mutations and biophysical characterization of amyloidogenic peptide fragments identified from lattice corneal dystrophy patients.
Anandalakshmi V; Murugan E; Leng EGT; Ting LW; Chaurasia SS; Yamazaki T; Nagashima T; George BL; Peh GSL; Pervushin K; Lakshminarayanan R; Mehta JS
Biochem J; 2017 May; 474(10):1705-1725. PubMed ID: 28381645
[TBL] [Abstract][Full Text] [Related]
12. Protein folding, misfolding and aggregation: A tale of constructive to destructive assembly.
Khan MV; Zakariya SM; Khan RH
Int J Biol Macromol; 2018 Jun; 112():217-229. PubMed ID: 29374532
[TBL] [Abstract][Full Text] [Related]
13. Non-polyphenolic natural inhibitors of amyloid aggregation.
Ma L; Yang C; Zheng J; Chen Y; Xiao Y; Huang K
Eur J Med Chem; 2020 Apr; 192():112197. PubMed ID: 32172082
[TBL] [Abstract][Full Text] [Related]
14. Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor.
Silva JL; Rangel LP; Costa DC; Cordeiro Y; De Moura Gallo CV
Biosci Rep; 2013 Jul; 33(4):. PubMed ID: 24003888
[TBL] [Abstract][Full Text] [Related]
15. A covalent homodimer probing early oligomers along amyloid aggregation.
Halabelian L; Relini A; Barbiroli A; Penco A; Bolognesi M; Ricagno S
Sci Rep; 2015 Sep; 5():14651. PubMed ID: 26420657
[TBL] [Abstract][Full Text] [Related]
16. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases.
Hekmatimoghaddam S; Zare-Khormizi MR; Pourrajab F
Biofactors; 2017 Nov; 43(6):737-759. PubMed ID: 26899445
[TBL] [Abstract][Full Text] [Related]
17. Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity.
Lasagna-Reeves CA; Clos AL; Castillo-Carranza D; Sengupta U; Guerrero-Muñoz M; Kelly B; Wagner R; Kayed R
Biochem Biophys Res Commun; 2013 Jan; 430(3):963-8. PubMed ID: 23261448
[TBL] [Abstract][Full Text] [Related]
18. p53 TAD2 Domain (38-61) Forms Amyloid-like Aggregates in Isolation.
Gadhave K; Kapuganti SK; Mishra PM; Giri R
ACS Chem Neurosci; 2022 Aug; 13(15):2281-2287. PubMed ID: 35856925
[TBL] [Abstract][Full Text] [Related]
19. Simulation Studies of Amyloidogenic Polypeptides and Their Aggregates.
Ilie IM; Caflisch A
Chem Rev; 2019 Jun; 119(12):6956-6993. PubMed ID: 30973229
[TBL] [Abstract][Full Text] [Related]
20. Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.
Palanikumar L; Karpauskaite L; Al-Sayegh M; Chehade I; Alam M; Hassan S; Maity D; Ali L; Kalmouni M; Hunashal Y; Ahmed J; Houhou T; Karapetyan S; Falls Z; Samudrala R; Pasricha R; Esposito G; Afzal AJ; Hamilton AD; Kumar S; Magzoub M
Nat Commun; 2021 Jun; 12(1):3962. PubMed ID: 34172723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
